Phio Pharmaceuticals Corp...

AI Score

0

Unlock

1.81
0.02 (1.12%)
At close: Feb 14, 2025, 3:59 PM
1.84
1.66%
After-hours Feb 14, 2025, 05:37 PM EST
undefined%
Bid 1.79
Market Cap 8.65M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -9.75
PE Ratio (ttm) -0.19
Forward PE n/a
Analyst Buy
Ask 1.84
Volume 243,833
Avg. Volume (20D) 6,556,770
Open 1.83
Previous Close 1.79
Day's Range 1.79 - 1.88
52-Week Range 1.53 - 10.35
Beta undefined

About PHIO

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic pr...

Industry Biotechnology
Sector Healthcare
IPO Date May 10, 2012
Employees 8
Stock Exchange NASDAQ
Ticker Symbol PHIO

Analyst Forecast

According to 1 analyst ratings, the average rating for PHIO stock is "Buy." The 12-month stock price forecast is $36, which is an increase of 1888.95% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
1 month ago
-25.7%
Phio Pharmaceuticals shares are trading lower afte... Unlock content with Pro Subscription
1 month ago
-45.76%
Phio Pharmaceuticals shares are trading lower after the company announced a $3.19 million registered direct offering.